Yearly Archives: 2021

Study Indicating that Omicron Represents a “Hybrid” Virus Containing RNA of a Common Cold Virus Could Place an Endpoint for Pandemic Lockdowns.

A preprint of a study on the possible origin of Omicron was recently published. The paper indicates that the new cousin of Covid-19 is, as suspected, a recombinant virus. What represents welcome news is that the recombinant is NOT an

Posted in Open Blog

US Pharmacists may be Permitted to Diagnose Covid-19 and Prescribe Paxlovid Directly.

“Pharmacists worry another job might soon be added to their to-do list: If regulators approve antiviral pills from drugmakers Merck and Pfizer to treat COVID-19, pharmacists may be able to diagnose infections and then prescribe pills to customers.” Pharmacist Prescriptive

Posted in Open Blog

Pfizer Inc. (PFE-$50.75, NYSE): Initial Analyst Modeling Suggests First Year Paxlovid Sales May Surpass $20 Billion US. Omicron Might Render that to Be a Conservative Estimate.

The head of drugmaker Moderna said that existing COVID-19 vaccines, in all likeliness, will prove to be less effective against the new Omicron variant causing worldwide concern. “There is no world, I think, where [the effectiveness] is the same level…

Posted in Open Blog

Grupo Comercial Chedraui (CHDRAUIB.MX- 41.46 ). The Transformative “US Centric” Purchase of Smart & Final is Only Partially Reflected in Q3 2021 Results.

Posted in Portfolio Model Subscription

Pfizer Inc.’s New Antiviral Cocktail to Combat Covid-19 Seems Likely to Turn the Tide on Hospitalizations. An Entire Industry Sector is Poised to Benefit Disproportionately as a Result.

Utilizing “off the shelf” research on SARS (Sudden Acute Respiratory Syndrome) era antivirals, Pfizer Inc (PFE-NYSE, $47.51) seems, more than likely, to have produced an elegant solution for a very pressing gap in the current approach to combatting Covid-19 infection.

Posted in Open Blog
Recent Comments